Thanks for the article. It gave a good history of the 60 years of development from the initial conception of MABR to the first launch by Oxymem in 2013 in Europe, followed by Zeelung in North America, and 2016 by Emefcy in China.
I feel the chart understated the amount of installations in the world, as we know, FLC already has more than 200 MABR plants installed by end of 2020.
From the article, the unique offer FLC has, is in the decentralized market and IMO, the more installations we have, the deeper a moat we have.
I am looking forward to Friday’s update, and would be keen to get some lights on the Aspiral Micro, as we have put some in for trials in October.
FLC Price at posting:
25.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)